Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, oral tofacitinib showed higher efficacy and tolerability in treating refractory alopecia totalis and universalis compared to traditional treatments, achieving a 50% improvement in severity scores for 44.4% of patients over six months, with fewer adverse effects.

This case study reports that a pediatric patient with recalcitrant alopecia areata was treated using a 308 nm excimer lamp and topical tofacitinib 2% gel.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

Dermoscopy helps diagnose frontal fibrosing alopecia by identifying specific scalp features.

This study found a high prevalence of beard and eyebrow alopecia in male patients with frontal fibrosing alopecia, and suggests a potential link between hormonal imbalances and the condition.

In this case report, a patient with early-stage Frontal Fibrosing Alopecia showed substantial improvement in follicular density and inflammation control after three monthly sessions of Botulinum Toxin Type A administered via microinfusion.

This paper presents consensus guidelines for standardized diagnostic criteria and assessment methods for frontal fibrosing alopecia to improve clinical research and data collection globally.

This meta-analysis found a significant positive association between frontal fibrosing alopecia and both sunscreen and moisturizer use, with the moisturizer association significant only in males.

This retrospective study evaluated the use of tofacitinib as an induction therapy for severe alopecia areata and found it promising and comparable to the standard oral mini-pulse treatment, though pulse steroids may be considered if tofacitinib response is inadequate.

The researchers reported a case where treatment with tofacitinib improved both hair loss and skin lesions in a patient with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa over six months, with no recurrence or adverse events during two-year follow-up.

The researchers reported that the novel MBTPS2 variant p.Glu172Asp found in a male proband is likely pathogenic, consistent with osteogenesis imperfecta symptoms and molecular signatures, including disrupted fatty acid metabolism and collagen production.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

This study reviewed 38 cases of frontal fibrosing alopecia, observing that diagnosis often occurs years after onset and is more prevalent in postmenopausal women.

In this case report, a female patient with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa showed significant improvement in symptoms, including hair loss and lesions, after six months of treatment with tofacitinib, with no recurrence or adverse effects over a two-year follow-up.

This study identified TGFβ-2 as a potential driver of progenitor cell loss in hair follicles from early androgenetic alopecia scalps, suggesting its role in the condition's molecular disturbances.

This study observed an alopecia syphilitica-like pattern of hair loss in a woman with frontal fibrosing alopecia, suggesting it may be another atypical presentation of the condition.

The researchers reported that dPGS-PCL as a carrier improved the penetration of tofacitinib in an ex-vivo human skin model compared to free tofacitinib, but did not show significant differences in inhibiting IL-6 and IL-8 during short incubation.

This study found that protein hydrolysates from mealworms, especially those derived using flavourzyme, significantly enhance adipogenic differentiation in 3T3-L1 preadipocytes, suggesting their potential as sustainable ingredients for glycemic control, skin health, and tissue regeneration products.

This study observed that insurance coverage for oral tofacitinib in alopecia areata patients was difficult to obtain, with 71% of patients ultimately not receiving approval despite the drug's efficacy as an off-label treatment.

This review discusses the various factors implicated in the etiology of frontal fibrosing alopecia and notes the need for effective treatments, reporting no new clinical findings.

This correspondence discusses proposed updates to the diagnostic criteria for frontal fibrosing alopecia, emphasizing the importance of differentiating it from other types of alopecia.

This study adds evidence suggesting a genetic component to frontal fibrosing alopecia, with daughters experiencing an earlier onset than their mothers, although the clinical pattern remains similar to non-familial cases.

Frontal fibrosing alopecia can affect men's beards and leads to permanent hair loss.

This study suggests that folliculin, mutated in Birt–Hogg–Dubé syndrome, and its partner FNIP1 may play a role in energy and nutrient sensing through the AMPK and mTOR pathways.

This study suggests that frontal fibrosing alopecia is a highly inflammatory disease involving TH1 and JAK-STAT pathways, without reduced hair keratins, highlighting JAK-STAT signaling as a potential therapeutic target.

This study identified two novel genes, pmg-1 and pmg-2, expressed in various skin and gland tissues and potentially involved in the differentiation of epithelial cells in epidermal appendages.

This report describes two unusual cases of frontal fibrosing alopecia in men, highlighting potential vaccine-related immune triggers and genetic factors, especially regarding the pronounced facial papular phenotype observed.

This study found that Follicular Maps, derived from trichoscopic images, remained consistent over time and unaffected by hair cycling or noncicatricial alopecia, offering a precise tool for diagnosing and monitoring hair and scalp conditions.

This paper discusses the importance of early diagnosis and treatment of polycystic ovarian syndrome to potentially reduce long-term complications like diabetes, hypertension, and heart disease, but reports no new clinical outcomes.